Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Brain & Neurology

Activation of PKA/SIRT1 signaling pathway by photobiomodulation therapy reduces Aβ levels in Alzheimer's disease models

We further found that the activity of the mitochondrial photoacceptor cytochrome c oxidase (CcO) was responsible for PBMT-induced activation of PKA and SIRT1.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

The authors studied photobiomodulation therapy (PBMT), a noninvasive light treatment, in mouse and cell models of Alzheimer's disease. They report that PBMT reduced amyloid-beta production and plaque formation by shifting amyloid precursor protein processing toward a nonamyloidogenic pathway, and improved memory in mice. The effect was linked to SIRT1 and the cAMP/PKA pathway, with cytochrome c oxidase activity implicated. These findings come from animal and cell experiments.

Who or what was studied
APP/PS1 and APPswe-expressing mouse models, primary neurons and SH-SY5Y cells
Limits stated in the abstract
The study used mouse and cell models rather than human participants, and the abstract does not report sample sizes.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

A hallmark of Alzheimer's disease (AD) is the accumulation of amyloid-β (Aβ), which correlates significantly with progressive cognitive deficits. Although photobiomodulation therapy (PBMT), as a novel noninvasive physiotherapy strategy, has been proposed to improve neuronal survival, decrease neuron loss, ameliorate dendritic atrophy, and provide overall AD improvement, it remains unknown whether and how this neuroprotective process affects Aβ levels. Here, we report that PBMT reduced Aβ production and plaque formation by shifting amyloid precursor protein (APP) processing toward the nonamyloidogenic pathway, thereby improving memory and cognitive ability in a mouse model of AD. More importantly, a pivotal protein, SIRT1, was involved in this process by specifically up-regulating ADAM10 and down-regulating BACE1, which is dependent on the cAMP/PKA pathway in APP/PS1 primary neurons and SH-SY5Y cells stably expressing human APP Swedish mutation (APPswe). We further found that the activity of the mitochondrial photoacceptor cytochrome c oxidase (CcO) was responsible for PBMT-induced activation of PKA and SIRT1. Together, our research suggests that PBMT as a viable therapeutic strategy has great potential value in improving cognitive ability and combatting AD.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a single study: what to check before relying on this kind of research.

Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Cytochrome c oxidase. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies